Experimental pill aims to shield the liver during cancer treatment
Disease control
Recruiting now
This trial tests whether an experimental drug called FB-1603 can protect liver function in people with liver cancer who are receiving a standard procedure called transarterial chemoembolization (TACE). Participants take either a low dose, a high dose, or a placebo capsule daily f…
Phase: PHASE1, PHASE2 • Sponsor: Febico Biomedical Corp. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC